Abstract
Background Statins may be protective in viral infection and have been proposed as treatment in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.
Objective We evaluated the effect of statins on mortality in four groups hospitalized with (SARS-CoV-2) infection (continued statin, newly initiated statin, discontinued statin, never on statin).
Design In a single center cohort study of 1179 patients hospitalized with SARS-CoV-2 infection, the outcome of death, Intensive Care Unit (ICU) admission or hospital discharge was evaluated. Patients’ statin use, laboratory data, and co-morbidities were determined via chart review and electronic health records. Using marginal structural models to account for timing of statin initiation and competing risks, we compared the likelihood of severe outcomes in the four statin exposure groups.
Setting Academic medical center in the United States
Participants Patients hospitalized with SARS-CoV-2 infection
Measurements 28-day mortality, ICU admission, or discharge
Results Among 1179 patients, 360 were never on a statin, 311 were newly initiated on a statin, 466 were continued on a statin, and 42 had a statin discontinued. In this cohort, 154 (13.1%) patients died by 28-days. With marginal structural model analysis, statin use reduced the hazard of 28-day mortality (HR 0.566 [CI 0.372, 0.862], p = 0.008). Both new initiation of statins (HR 0.493 [CI 0.253, 0.963], p=0.038) and continuing statin therapy reduced the hazard of 28-day mortality (HR 0.270 [CI 0.114, 0.637], p=0.003). Sensitivity analysis found that statin use was associated with improved mortality for patients > 65 years, but not for patients 65 years or younger.
Limitation Observational design
Conclusion Statin therapy during hospitalization for SARS-CoV-2 infection, including new initiation and continuation of therapy, was associated with reduced short-term mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for this study was provided by the MGH Division of Clinical Research. Funding was used primarily to support the MGH COVID-19 registry development. Several of the authors individually have received research grants that are specified in the disclosures section of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the MGH Institutional Review Board (IRB # 2020P000829); a waiver of informed consent was granted.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This data was obtained from the MGH Covid-19 Data registry. Readers can contact the corresponding author for further information.
Abbreviations
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- COVID-19
- Coronavirus disease 2019
- MGH
- Massachusetts General Hospital
- ACE-2
- Angiotensin-converting enzyme-2
- AST
- Aspartate Aminotransferase test
- ALT
- Alanine Aminotransferase test
- ICU
- Intensive Care Unit
- HR
- Hazard Ratio
- CI
- Confidence Interval
- ARDS
- acute respiratory distress syndrome
- EDW
- Enterprise Data Warehouse
- BMI
- Body Mass Index
- WBC
- white blood cell count
- CRP
- C-reactive protein
- HIV
- Human Immunodeficiency Virus
- COPD
- Chronic Obstructive Pulmonary Disease
- ILD
- Interstitial Lung Disease
- IQR
- Interquartile range
- NAFLD
- Non-alcoholic Fatty Liver Disease
- ALC
- Absolute lymphocyte count
- CK
- Creatine Kinase
